PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · USD

$0.38

+0.04 (+11.7%)· Recorded snapshot

Market cap	4.1M
Net income (ttm)	-20.6M
EPS (ttm)	-$2.20
Shares out	10.7M
Volume	901,450
Beta	0.77

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -20.6M
EPS (ttm): -$2.20
Market cap: 4.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 20:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-44

P25 n/aP50 n/aP75 n/a

ROIC-9.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PMCB indicators

Market & fundamental data

Available fields

183

Groups with data

Currency

USD

Showing 183 of 183 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001157075
Company name	PharmaCyte Biotech, Inc.
Country	United States
Country code	US
CUSIP number	71715X203
Earnings date	2026-12-17
Earnings time	amc
Employees	2
Employees change	0
Employees growth	0%
Enterprise value	$-26.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-07-31
First seen	2026-05-09
Fiscal year end	April
Founded	1996
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US71715X2036
Last 10-K release date	2026-07-29
Last earnings date	2026-09-14
Last refreshed	2026-11-04
Last stock split date	2021-07-12
Last stock split type	Reverse
Market cap	$4.1M
Market cap category	Nano-Cap
Next earnings date	2026-12-17
Options	Yes
Price	$0.38
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-11-04
Symbol	PMCB
U.S. state	Nevada
Website	https://pharmacyte.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-579.87%
FCF / EV yield	14.94%
FCF yield	-95.12%
P/B ratio	0.13x
Price / tangible book value	0.15x
Sector forward P/E	24x
Sector P/E	49.18x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-10.3M
ROA	-8.35%
ROA (5Y)	-5.58%
ROCE	-15.2%
ROE	-43.99%
ROE (5Y)	1.77%
ROIC	-9.3%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth quarters	1
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-5.5M
EPS	$-2.20
FCF per share	$-0.37
Financing cash flow	$6.5M
Free cash flow	$-3.9M
Free cash flow minus SBC	$-5M
Investing cash flow	$2M
Net cash flow	$4.6M
Net income	$-20.6M
Operating cash flow minus SBC	$-5M
Operating income	$-5.5M
Stock-based compensation	$1.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$2.60
Debt / equity	0
Long-term assets	$5.7M
Long-term liabilities	$6.1M
Net cash (debt)	$30.5M
Net cash / market cap	736.72%
Net cash growth	127.03%
Net debt / equity	-1.02
Piotroski F-Score	2
Shareholders' equity	$29.8M
Tangible book value	$27.9M
Tangible book value per share	$2.60
Total assets	$36.7M
Total cash	$30.5M
Total debt	$0
Total liabilities	$6.9M
WACC	8.5%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$31M
Current liabilities	$768,682
Current ratio	40.3
Net working capital	$-307,528
Quick ratio	40.25
Working capital	$30.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-32.59%
Dividend yield	0%
Shareholder yield	-32.59%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.25%
10Y return CAGR	-38.7%
10Y total return	-99.25%
150-day SMA	$0.60
15Y price change	-99.52%
15Y return CAGR	-29.97%
15Y total return	-99.52%
1D price change	11.73%
1M price change	-1.6%
1M total return	-1.6%
1W price change	17.63%
1W total return	17.63%
1Y price change	-57.09%
1Y return CAGR	-57.11%
1Y total return	-57.09%
20-day SMA	$0.35
200-day SMA	$0.64
20Y price change	-99.86%
20Y return CAGR	-27.96%
20Y total return	-99.86%
3M price change	-31.63%
3M total return	-31.63%
3Y price change	-82.35%
3Y return CAGR	-43.89%
3Y total return	-82.35%
50-day SMA	$0.41
50-day SMA vs 200-day SMA	50under200
52-week high	$1.51
52-week high date	2025-12-05
52-week low	$0.30
52-week low date	2026-10-30
5Y price change	-86.52%
5Y return CAGR	-33.02%
5Y total return	-86.52%
6M price change	-47.88%
6M total return	-47.88%
After-hours change	0.26%
After-hours close	$0.34
After-hours price	$0.34
All-time high	$1,249.93
All-time high date	2003-10-08
All-time low	$0.30
All-time low date	2026-10-30
Average true range (ATR)	$0.04
Average volume	102.6K
Beta (1Y)	1.96
Beta (2Y)	0.93
Beta (5Y)	0.77
Change from 52-week high	-74.83%
Change from 52-week low	25.79%
Change from all-time high	-99.97%
Change from all-time low	30.32%
Change from open	12.76%
Day's gap	-0.91%
Dollar volume	$342,551
High price	$0.42
Low price	$0.34
Monthly RSI	32.54
Open price	$0.34
Position in 52-week range	51.19%
Previous close	$0.34
Price vs 150-day SMA	-34.54%
Price vs 20-day SMA	12.29%
Price vs 200-day SMA	-38.13%
Price vs 50-day SMA	-3.95%
Relative volume	8.78
RSI	56.22
Sharpe ratio	-0.43
Sharpe ratio (3Y)	-0.42
Sharpe ratio (5Y)	-0.38
Sortino ratio	-0.7
Sortino ratio (3Y)	-0.6
Sortino ratio (5Y)	-0.5
Volume	901.5K
Weekly RSI	36.75
YTD price change	-45.62%
YTD total return	-45.62%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	10.1M
Float percentage	93.79%
Shares change (QoQ)	0.72%
Shares change (YoY)	32.59%
Shares held by insiders	5.74%
Shares held by institutions	7.18%
Shares outstanding	10.7M
Short % of float	0.7%
Short % of shares	0.65%
Short ratio	0.2 days

Deeper analysis on PMCB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PMCB report

Is a complete PMCB research report available?

No complete published report is available for PharmaCyte Biotech, Inc. (PMCB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

PharmaCyte Biotech, Inc. (PMCB)

Price

Financial snapshot

Fair-value bridge

Latest news · PMCB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PMCB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PMCB

Frequently asked questions